Safety and efficacy of transcatheter tricuspid valve replacement with LuX-Valve in patients with severe tricuspid regurgitation.
10.3760/cma.j.cn112148-20210125-00091
- Author:
Xiao Ping NING
1
;
Zhao AN
1
;
Fan QIAO
1
;
Cheng Liang CAI
1
;
Lin HAN
1
;
Zhi Gang SONG
1
;
Bai Ling LI
1
;
Guang Wei ZHOU
1
;
Jun WANG
1
;
Zhi Yun XU
1
;
Fang Lin LU
1
Author Information
1. Department of Cardiovascular Surgery, Changhai Hospital, Naval Medical University, Shanghai 200433, China.
- Publication Type:Observational Study
- MeSH:
Aged;
Cardiac Catheterization;
Female;
Heart Valve Prosthesis Implantation;
Humans;
Male;
Middle Aged;
Severity of Illness Index;
Time Factors;
Treatment Outcome;
Tricuspid Valve/surgery*;
Tricuspid Valve Insufficiency/surgery*
- From:
Chinese Journal of Cardiology
2021;49(5):455-460
- CountryChina
- Language:Chinese
-
Abstract:
Objectives: To evaluate the safety and efficacy of LuX-Valve on the treatment of severe tricuspid regurgitation (TR). Methods: This is a prospective observational study. From September 2018 to March 2019, 12 patients with severe TR, who were not suitable for surgery, received LuX-Valve implantation in Changhai Hospital. LuX-Valve was implanted under general anesthesia and the guidance of transesophageal echocardiography and X-ray fluoroscopy. Access to the tricuspid valve was achieved via a minimally invasive thoracotomy and transatrial approach. Main endpoints were surgery success and device success. Surgery success was defined as successful implanting the device and withdrawing the delivery system, positioning the valve correctly and stably without severe or life-threatening adverse events. Device success was defined as satisfied valve function (TR severity reduction ≥ 2 grades, tricuspid gradient ≤ 6 mmHg (1 mmHg=0.133 kPa)), absence of malposition, valve failure and reintervention, major adverse events including device related mortality, embolization, conduction system disturbances and new onset shunt across ventricular septum at day 30 post implantation. Results: A total of 12 patients with severe to torrential TR were included in this study. The age was (68.5±6.9) years and 7 were female. All patients had typical right heart failure symptoms. Procedural success was achieved in all cases, there was no intraprocedural mortality or transfer to open surgery. TR significantly improved after LuX-Valve implantation (none/trivial in 8 patients, mild in 3 patients and moderate in 1 patient). The average device time was (9.2±4.2) minutes. Intensive care unit duration was 3.0 (2.0, 4.8) days. One patient died at postoperative day 18 due to non-surgery and device reasons. Transthoracic echocardiography at 30 days after operation showed that TR was significantly reduced (none/trivial in 8 patients, mild in 2 patients and moderate in 1 patient) and device success was achieved in 11 cases. All survived patients experienced a significant improvement in life quality with significantly improvement in New York Heart Association (NYHA) classification (Ⅰ and Ⅱ: 6/11 post operation vs. 0/11 before operation, P=0.012) and there were no device related complications in this patient cohort. Conclusions: LuX-Valve implantation is feasible, safe and effective for the treatment of patients with severe TR.
